Navigation Links
Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
Date:3/13/2008

December 2007, Jazz Pharmaceuticals dosed the first patient in an ongoing Phase II clinical trial of JZP-8. Assuming successful results from the Phase II trial, Jazz Pharmaceuticals expects to initiate a Phase III clinical development program for JZP-8 in the first half of 2009.

Jazz Pharmaceuticals' product candidate for once-daily treatment of epilepsy and bipolar disorder, JZP-4, incorporates a new chemical entity that inhibits both sodium and calcium channels in vitro and has shown efficacy in animal models. Two proof-of-concept clinical studies in healthy volunteers and patients demonstrated activity in well-validated epilepsy models. Jazz Pharmaceuticals plans to begin enrolling subjects in a Phase II trial of JZP-4 for the treatment of epilepsy during the third quarter of 2008.

Jazz Pharmaceuticals also disclosed three additional early-stage programs: a solid oral dosage form of sodium oxybate; a new chemical entity that is a structural analog of valproic acid for the treatment of epilepsy and bipolar disorder; and a new chemical entity that is a triple reuptake inhibitor for major depressive disorder. Both of the new chemical entities are in early feasibility studies and Jazz Pharmaceuticals has established clear targets to advance them into full development.

Financial Updates

Jazz Pharmaceuticals provided guidance forecasting selling, general and administrative expenses during 2008 to be in the range of $130 million to $140 million, reflecting the expanded sales force, launch activities related to LUVOX CR and costs associated with being a public company. Research and development spending during 2008 is expected to be in the range of $60 million to $70 million.

Jazz Pharmaceuticals also announced that it has amended its agreement with Solvay Pharmaceuticals, Inc., to defer the payment of milestones triggered by the approval and launch of LUVOX CR.

A webcast of Jazz Pharmaceuticals' Investor Day is available on the i
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
2. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
3. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
4. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
5. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
6. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
7. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
8. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
9. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
10. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
11. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... 2014 The “LoveHandle" was featured on ... Report, which features the latest and coolest technology products ... expert and technology reporter for NewsWatch, conducted the product ... phones off the ground. , According to eMarketer, US ... operating a mobile device, and that doesn’t include talking. ...
(Date:10/26/2014)... 26, 2014 Revenue Masters Cloud Contract ... user-friendly software recently launched. Cloud Contract Modeling™ ... rates, including bundled payments and government reimbursement. Instead of ... be automatically checked against the payer contract to ensure ... , Revenue Masters, LLC, is a healthcare revenue cycle ...
(Date:10/25/2014)... Triton Algae Innovations, ... Dr. Xun Wang has joined the firm as ... Triton has developed a patented synthetic biology platform for ... Dr. Wang, the platform uses algae to produce novel ... “Algae are unique because they can produce compounds that ...
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... Wisconsin (PRWEB) October 25, 2014 QueenBeeTickets.com ... for a great selection at affordable prices. Bob Seger ... Center Huntington Center and Nationwide Arena are going on ... , Click Here to browse the selection ... Band at QueenBeeTickets.com. , The famous singer is touring ...
Breaking Medicine News(10 mins):Health News:A New Method for Keeping Mobile Devices from Falling was Featured on NewsWatch Television on October 16, 2014 2Health News:Keeping Hospitals Doors Open with Affordable Software Now Available 2Health News:Keeping Hospitals Doors Open with Affordable Software Now Available 3Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- ... massive egg recall due to salmonella contamination has probably made you ... But now some time has passed, and you,re starting to ... the eggs languishing in your fridge or are you inviting a ...
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- If ... overindulgence can be easily worked off at the gym, think ... month,s worth of unhealthy living changes physiology, making piled-on fat ... can have later long-term effects," said study co-author Dr. Torbjorn ...
... physical and emotional problems a year after surgery than before ... the key findings of a research study of more than ... Surgery . Researchers from The Netherlands spoke to ... 54, who had undergone planned surgery, ranging from plastic surgery ...
... HealthDay Reporter , TUESDAY, Aug. 24 (HealthDay News) -- A ... death after taking the glucose-lowering diabetes drugs Avandia and Actos ... to numerous other studies that found that the risk was ... findings are, however, in line with some other previous studies, ...
... times could be cut by over one third and patients, ... approach to the triage process of sorting patients for ... International Journal of Six Sigma and Competitive Advantage ... Zarqa, Jordan and colleagues have turned to a design strategy ...
... Reporter , TUESDAY, Aug. 24 (HealthDay News) -- Pregnant ... should not worry that their use will cause birth ... of women develop herpes simplex during the first trimester ... antiviral drugs such as acyclovir (Zovirax), valacyclovir (Valtrex) and ...
Cached Medicine News:Health News:Are The Eggs in Your Fridge Safe to Eat? 2Health News:Are The Eggs in Your Fridge Safe to Eat? 3Health News:Are The Eggs in Your Fridge Safe to Eat? 4Health News:Short-Term Overeating Could Make Long-Term Weight Loss Tougher 2Health News:Up to 1 in 4 patients report more physical problems a year after surgery than before 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 3Health News:Engineering shorter wait times in the ER 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 3
(Date:10/25/2014)... Md. , Oct. 24, 2014  The ... highlighted the latest results achieved by ... system. The National Precursor Log ... at the point of sale and helps flag ... narcotics agents often set up NPLEx "watch lists" ...
(Date:10/25/2014)... 2014 In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to the ... internet on Monday, November 3, 2014 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
(Date:10/25/2014)... 24, 2014 Best Practices designed the ... with a forum for sharing insights about the ... a mechanism for creating and sharing solutions through ... findings from the Medical Affairs Consortium survey. ... for the first roundtable of the 2014-2015 Medical ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has ... mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, ... mg, 10 mg/40 mg and 10 mg/80 mg, the generic version ... treatment of hypertension. Caduet Tablets had U.S. sales ...
... Inc. reported today that it has completed enrollment in ... product expressing the neurturin (NRTN) gene for the treatment ... patients at 11 medical centers throughout the United States.  ... provide constant, sustained expression of neurturin (NRTN), a neurotrophic ...
Cached Medicine Technology:Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 2Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 3Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: